|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: WDR13 |
Gene summary for WDR13 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | WDR13 | Gene ID | 64743 |
| Gene name | WD repeat domain 13 | |
| Gene Alias | MG21 | |
| Cytomap | Xp11.23 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9H1Z4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64743 | WDR13 | P126T-E | Human | Esophagus | ESCC | 5.37e-03 | 6.48e-01 | 0.1125 |
| 64743 | WDR13 | P127T-E | Human | Esophagus | ESCC | 9.54e-07 | 4.51e-02 | 0.0826 |
| 64743 | WDR13 | P128T-E | Human | Esophagus | ESCC | 2.55e-12 | 3.71e-01 | 0.1241 |
| 64743 | WDR13 | P130T-E | Human | Esophagus | ESCC | 8.57e-48 | 9.14e-01 | 0.1676 |
| 64743 | WDR13 | S43 | Human | Liver | Cirrhotic | 3.09e-05 | -1.70e-01 | -0.0187 |
| 64743 | WDR13 | HCC1_Meng | Human | Liver | HCC | 1.49e-82 | 9.45e-02 | 0.0246 |
| 64743 | WDR13 | HCC2_Meng | Human | Liver | HCC | 8.24e-21 | 4.21e-02 | 0.0107 |
| 64743 | WDR13 | cirrhotic1 | Human | Liver | Cirrhotic | 3.29e-04 | 1.89e-01 | 0.0202 |
| 64743 | WDR13 | cirrhotic2 | Human | Liver | Cirrhotic | 1.71e-06 | 2.34e-01 | 0.0201 |
| 64743 | WDR13 | cirrhotic3 | Human | Liver | Cirrhotic | 3.83e-05 | 2.15e-01 | 0.0215 |
| 64743 | WDR13 | HCC1 | Human | Liver | HCC | 4.49e-33 | 6.20e+00 | 0.5336 |
| 64743 | WDR13 | HCC2 | Human | Liver | HCC | 8.16e-11 | 3.95e+00 | 0.5341 |
| 64743 | WDR13 | Pt13.b | Human | Liver | HCC | 7.22e-10 | 1.60e-01 | 0.0251 |
| 64743 | WDR13 | S014 | Human | Liver | HCC | 3.49e-10 | 7.19e-01 | 0.2254 |
| 64743 | WDR13 | S015 | Human | Liver | HCC | 2.24e-09 | 7.53e-01 | 0.2375 |
| 64743 | WDR13 | S016 | Human | Liver | HCC | 8.26e-14 | 6.69e-01 | 0.2243 |
| 64743 | WDR13 | S027 | Human | Liver | HCC | 5.57e-19 | 1.98e+00 | 0.2446 |
| 64743 | WDR13 | S028 | Human | Liver | HCC | 1.07e-33 | 1.86e+00 | 0.2503 |
| 64743 | WDR13 | S029 | Human | Liver | HCC | 2.39e-35 | 2.25e+00 | 0.2581 |
| 64743 | WDR13 | C04 | Human | Oral cavity | OSCC | 7.13e-26 | 1.26e+00 | 0.2633 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00443423 | Esophagus | ESCC | type B pancreatic cell proliferation | 15/8552 | 21/18723 | 1.54e-02 | 4.96e-02 | 15 |
| GO:005067310 | Oral cavity | OSCC | epithelial cell proliferation | 212/7305 | 437/18723 | 2.82e-05 | 2.61e-04 | 212 |
| GO:005067810 | Oral cavity | OSCC | regulation of epithelial cell proliferation | 180/7305 | 381/18723 | 5.88e-04 | 3.35e-03 | 180 |
| GO:005067324 | Skin | cSCC | epithelial cell proliferation | 144/4864 | 437/18723 | 6.07e-04 | 4.38e-03 | 144 |
| GO:004434211 | Skin | cSCC | type B pancreatic cell proliferation | 11/4864 | 21/18723 | 8.71e-03 | 4.01e-02 | 11 |
| GO:0050673111 | Thyroid | ATC | epithelial cell proliferation | 174/6293 | 437/18723 | 3.49e-03 | 1.55e-02 | 174 |
| GO:0050678110 | Thyroid | ATC | regulation of epithelial cell proliferation | 151/6293 | 381/18723 | 7.47e-03 | 2.92e-02 | 151 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| WDR13 | SNV | Missense_Mutation | c.541N>A | p.Ala181Thr | p.A181T | Q9H1Z4 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A2-A3Y0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| WDR13 | SNV | Missense_Mutation | novel | c.455C>T | p.Thr152Met | p.T152M | Q9H1Z4 | protein_coding | tolerated(0.09) | possibly_damaging(0.812) | TCGA-AR-A2LK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | anastrozole | PD |
| WDR13 | SNV | Missense_Mutation | c.718N>G | p.Thr240Ala | p.T240A | Q9H1Z4 | protein_coding | deleterious(0.05) | benign(0.03) | TCGA-E2-A15M-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| WDR13 | SNV | Missense_Mutation | novel | c.1166N>G | p.Asn389Ser | p.N389S | Q9H1Z4 | protein_coding | tolerated(0.53) | benign(0.358) | TCGA-E2-A570-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| WDR13 | SNV | Missense_Mutation | c.962C>T | p.Ala321Val | p.A321V | Q9H1Z4 | protein_coding | tolerated(0.12) | possibly_damaging(0.532) | TCGA-E9-A1N9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| WDR13 | deletion | Frame_Shift_Del | novel | c.319delN | p.His108ThrfsTer16 | p.H108Tfs*16 | Q9H1Z4 | protein_coding | TCGA-A7-A0D9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | ||
| WDR13 | SNV | Missense_Mutation | rs782786399 | c.631C>T | p.Arg211Cys | p.R211C | Q9H1Z4 | protein_coding | tolerated(0.33) | benign(0) | TCGA-MY-A5BE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| WDR13 | SNV | Missense_Mutation | novel | c.97N>T | p.Arg33Trp | p.R33W | Q9H1Z4 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-AA-3549-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| WDR13 | SNV | Missense_Mutation | novel | c.247N>A | p.Val83Ile | p.V83I | Q9H1Z4 | protein_coding | tolerated(0.43) | benign(0.005) | TCGA-AA-3854-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| WDR13 | SNV | Missense_Mutation | rs782245413 | c.535N>T | p.Arg179Cys | p.R179C | Q9H1Z4 | protein_coding | deleterious(0) | possibly_damaging(0.498) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |